{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:17:13Z","timestamp":1790259433574,"version":"4.1.0"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where ALK represents a rational therapeutic target in these settings. In this study, we report the identification and biological characterization of X-376 and X-396, two potent and highly specific ALK small molecule tyrosine kinase inhibitors (TKIs). In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 and X-396 were more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066 (PF-1066), an ALK\/MET dual TKI currently in clinical trials. Both X-376 and X-396 displayed potent antitumor activity in vivo with favorable pharmacokinetic and toxicity profiles. Similar levels of drug sensitivity were displayed by the three most common ALK fusion proteins in lung cancer (EML4-ALK variants E13;A20, E20;A20, and E6b;A20) as well as a KIF5B\u2013ALK fusion protein. Moreover, X-396 could potently inhibit ALK kinases engineered with two point mutations associated with acquired resistance to PF-1066, L1196M, and C1156Y, when engineered into an E13;A20 fusion variant. Finally, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin. Our findings offer preclinical proof-of-concept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven malignancies. Cancer Res; 71(14); 4920\u201331. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-10-3879","type":"journal-article","created":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T01:07:42Z","timestamp":1306372062000},"page":"4920-4931","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":194,"title":["Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors"],"prefix":"10.1158","volume":"71","author":[{"given":"Christine M.","family":"Lovly","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medicine and 2Biostatistics, Vanderbilt University, Nashville, Tennessee; 3Max Planck Institute for Neurological Research, Klaus-Joachim-Z\u00fclich Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, Cologne, Germany; 4Anti-tumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center, New York City, New York; 5Department of Internal Medicine and Center of Integrated Oncology K\u00f6ln-Bonn, University of K\u00f6ln, K\u00f6ln, Germany; and 6Xcovery Inc., West Palm Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Heuckmann","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medicine and 2Biostatistics, Vanderbilt University, Nashville, Tennessee; 3Max Planck Institute for Neurological Research, Klaus-Joachim-Z\u00fclich Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, Cologne, Germany; 4Anti-tumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center, New York City, New York; 5Department of Internal Medicine and Center of Integrated Oncology K\u00f6ln-Bonn, University of K\u00f6ln, K\u00f6ln, Germany; and 6Xcovery Inc., West Palm Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medicine and 2Biostatistics, Vanderbilt University, Nashville, Tennessee; 3Max Planck Institute for Neurological Research, Klaus-Joachim-Z\u00fclich Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, Cologne, Germany; 4Anti-tumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center, New York City, New York; 5Department of Internal Medicine and Center of Integrated Oncology K\u00f6ln-Bonn, University of K\u00f6ln, K\u00f6ln, Germany; and 6Xcovery Inc., West Palm Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Chen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medicine and 2Biostatistics, Vanderbilt University, Nashville, Tennessee; 3Max Planck Institute for Neurological Research, Klaus-Joachim-Z\u00fclich Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, Cologne, Germany; 4Anti-tumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center, New York City, New York; 5Department of Internal Medicine and Center of Integrated Oncology K\u00f6ln-Bonn, University of K\u00f6ln, K\u00f6ln, Germany; and 6Xcovery Inc., West Palm Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman K.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medicine and 2Biostatistics, Vanderbilt University, Nashville, Tennessee; 3Max Planck Institute for Neurological Research, Klaus-Joachim-Z\u00fclich Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, Cologne, Germany; 4Anti-tumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center, New York City, New York; 5Department of Internal Medicine and Center of Integrated Oncology K\u00f6ln-Bonn, University of K\u00f6ln, K\u00f6ln, Germany; and 6Xcovery Inc., West Palm Beach, Florida"},{"name":"Authors' Affiliations: Departments of 1Medicine and 2Biostatistics, Vanderbilt University, Nashville, Tennessee; 3Max Planck Institute for Neurological Research, Klaus-Joachim-Z\u00fclich Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, Cologne, Germany; 4Anti-tumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center, New York City, New York; 5Department of Internal Medicine and Center of Integrated Oncology K\u00f6ln-Bonn, University of K\u00f6ln, K\u00f6ln, Germany; and 6Xcovery Inc., West Palm Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Liang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medicine and 2Biostatistics, Vanderbilt University, Nashville, Tennessee; 3Max Planck Institute for Neurological Research, Klaus-Joachim-Z\u00fclich Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, Cologne, Germany; 4Anti-tumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center, New York City, New York; 5Department of Internal Medicine and Center of Integrated Oncology K\u00f6ln-Bonn, University of K\u00f6ln, K\u00f6ln, Germany; and 6Xcovery Inc., West Palm Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Pao","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medicine and 2Biostatistics, Vanderbilt University, Nashville, Tennessee; 3Max Planck Institute for Neurological Research, Klaus-Joachim-Z\u00fclich Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, Cologne, Germany; 4Anti-tumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center, New York City, New York; 5Department of Internal Medicine and Center of Integrated Oncology K\u00f6ln-Bonn, University of K\u00f6ln, K\u00f6ln, Germany; and 6Xcovery Inc., West Palm Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,7,14]]},"reference":[{"key":"2022061702564314900_bib1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"2022061702564314900_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0002-9440(10)64550-6","article-title":"TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors","volume":"157","author":"Lawrence","year":"2000","journal-title":"Am J Pathol"},{"key":"2022061702564314900_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"2022061702564314900_bib4","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-07-6158","article-title":"Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer","volume":"68","author":"Choi","year":"2008","journal-title":"Cancer Res"},{"key":"2022061702564314900_bib5","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061702564314900_bib6","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-08-1018","article-title":"Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts","volume":"14","author":"Takeuchi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061702564314900_bib7","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-08-3248","article-title":"KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer","volume":"15","author":"Takeuchi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061702564314900_bib8","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"2022061702564314900_bib9","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1200\/JCO.2009.23.6661","article-title":"EML4-ALK: honing in on a new target in non-small-cell lung cancer","volume":"27","author":"Horn","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061702564314900_bib10","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"2022061702564314900_bib11","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Mosse","year":"2008","journal-title":"Nature"},{"key":"2022061702564314900_bib12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature07397","article-title":"Activating mutations in ALK provide a therapeutic target in neuroblastoma","volume":"455","author":"George","year":"2008","journal-title":"Nature"},{"key":"2022061702564314900_bib13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature07398","article-title":"Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma","volume":"455","author":"Janoueix-Lerosey","year":"2008","journal-title":"Nature"},{"key":"2022061702564314900_bib14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07399","article-title":"Oncogenic mutations of ALK kinase in neuroblastoma","volume":"455","author":"Chen","year":"2008","journal-title":"Nature"},{"key":"2022061702564314900_bib15","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1158\/1535-7163.MCT-09-0423","article-title":"GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers","volume":"8","author":"Sabbatini","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"2022061702564314900_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1073\/pnas.0609412103","article-title":"Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK","volume":"104","author":"Galkin","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022061702564314900_bib17","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","article-title":"An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms","volume":"67","author":"Zou","year":"2007","journal-title":"Cancer Res"},{"key":"2022061702564314900_bib18","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"2022061702564314900_bib19","doi-asserted-by":"crossref","first-page":"19893","DOI":"10.1073\/pnas.0805381105","article-title":"A mouse model for EML4-ALK-positive lung cancer","volume":"105","author":"Soda","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022061702564314900_bib20","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"2022061702564314900_bib21","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022061702564314900_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"2022061702564314900_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2022061702564314900_bib24","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/dji238","article-title":"Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations","volume":"97","author":"Mukohara","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2022061702564314900_bib25","doi-asserted-by":"crossref","first-page":"e4576","DOI":"10.1371\/journal.pone.0004576","article-title":"Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines","volume":"4","author":"Gandhi","year":"2009","journal-title":"PLoS One"},{"key":"2022061702564314900_bib26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ng.349","article-title":"Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer","volume":"41","author":"van Haaften","year":"2009","journal-title":"Nat Genet"},{"key":"2022061702564314900_bib27","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1535-7163.MCT-08-0374","article-title":"HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells","volume":"7","author":"Bachleitner-Hofmann","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2022061702564314900_bib28","doi-asserted-by":"crossref","first-page":"8878","DOI":"10.1016\/S0021-9258(19)52477-2","article-title":"Characterization of the asialoglycoprotein receptor in a continuous hepatoma line","volume":"256","author":"Schwartz","year":"1981","journal-title":"J Biol Chem"},{"key":"2022061702564314900_bib29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4161\/cbt.6.5.4003","article-title":"Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors","volume":"6","author":"Yuza","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"2022061702564314900_bib30","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1158\/0008-5472.CAN-07-6186","article-title":"Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors","volume":"68","author":"McDermott","year":"2008","journal-title":"Cancer Res"},{"key":"2022061702564314900_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.taap.2009.03.011","article-title":"An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells","volume":"237","author":"Noor","year":"2009","journal-title":"Toxicol Appl Pharmacol"},{"key":"2022061702564314900_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.3509","article-title":"Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066","volume":"27","author":"Kwak","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061702564314900_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-010-0128-6","article-title":"High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer","volume":"99","author":"Clarke","year":"2010","journal-title":"J Neurooncol"},{"key":"2022061702564314900_bib34","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","article-title":"The biology and treatment of EML4-ALK non-small cell lung cancer","volume":"46","author":"Sasaki","year":"2010","journal-title":"Eur J Cancer"},{"key":"2022061702564314900_bib35","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N Engl J Med"},{"key":"2022061702564314900_bib36","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/sj.onc.1210346","article-title":"Oncogenic tyrosine kinase NPM\/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway","volume":"26","author":"Marzec","year":"2007","journal-title":"Oncogene"},{"key":"2022061702564314900_bib37","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/sim.3005","article-title":"Quantifying synergism\/antagonism using nonlinear mixed-effects modeling: a simulation study","volume":"27","author":"Boik","year":"2008","journal-title":"Stat Med"},{"key":"2022061702564314900_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"2022061702564314900_bib39","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd1579","article-title":"Strategies to overcome resistance to targeted protein kinase inhibitors","volume":"3","author":"Daub","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"2022061702564314900_bib40","doi-asserted-by":"crossref","first-page":"9827","DOI":"10.1158\/0008-5472.CAN-10-1671","article-title":"Inhibition of ALK, PI3K\/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene","volume":"70","author":"Chen","year":"2010","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/14\/4920\/2654951\/4920.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/14\/4920\/2654951\/4920.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:55:49Z","timestamp":1655452549000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/71\/14\/4920\/567763\/Insights-into-ALK-Driven-Cancers-Revealed-through"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,14]]},"references-count":40,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2011,7,14]]},"published-print":{"date-parts":[[2011,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-10-3879","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22388153","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22388156","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22388153.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22388150","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22388150.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22388159.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22388156.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6502142","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6502142.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22388159","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,14]]}}}